Vivos Therapeutics, Inc. (NASDAQ: VVOS) shares are experiencing a significant rise on the US stock charts, witnessing a 5.37% increase during the pre-market session, reaching $2.55. This upward trend in VVOS stock is attributed to a pivotal announcement that has invigorated investor interest and optimism surrounding the company’s future.
AMA Issues New CPT Codes
Vivos (VVOS) has announced that new Current Procedural Terminology (CPT) codes have been created by the American Medical Association (AMA) and are applicable to all Vivos CARE oral medical devices. These codes will go into effect on January 1, 2025.
For individuals with obstructive sleep apnea (OSA) and the medical professionals who treat them, this announcement is very significant. The launch of these codes will improve coverage and payment prospects from commercial insurance companies. Vivos’s CARE oral medical devices are the only FDA-cleared devices intended to treat moderate to severe OSA.
Enhanced Patient Accessibility
The issuance of these new CPT codes is anticipated to expand access to Vivos’s proprietary airway remodeling technology, allowing a broader demographic of patients to effectively manage their OSA.
This strategic timing aligns well with Vivos’s recent regulatory approvals and a newly established alliance-based marketing and distribution model, positioning the company to foster substantial revenue growth.
Implications of CPT 2025 Updates
The AMA highlighted that advancements in medical innovations and technologies largely drive the updates reflected in the CPT 2025 code set, which includes a total of 420 revisions—270 new codes, 112 deletions, and 38 modifications.
This code set serves as a cornerstone for the efficient exchange of standardized information within a data-driven healthcare system, ultimately aiming to improve patient care, enhance clinical outcomes, and reduce costs.
The approval of these new CPT codes marks a significant regulatory and reimbursement milestone for Vivos, building upon the recent Medicare coverage approval the company received.
This progress underscores VVOS’s dedication to making OSA treatment more accessible and affordable, especially for younger patients aged 6 to 17, while ensuring that individuals receive the necessary support from their healthcare insurance plans.
